• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Comprehensive care of adults with respiratory diseases must include vaccines
Vaccines are among the most effective tools we have to improve and save lives, but only if they are administered to eligible patients. In this issue, Naeger et al1 highlight the major opportunities that the health care community has to achieve high adult vaccination rates. These vaccines include those for prevention of coronavirus disease 2019 (COVID-19), pneumococcal, and influenza, diseases that respiratory health professionals are most aware of, plus pertussis (in Tdap), herpes zoster (HZ, shingles), and as of May 3, 2023, respiratory syncytial viral, for which adults with asthma and chronic obstructive pulmonary diseas...
Source: Annals of Allergy, Asthma and Immunology - September 1, 2023 Category: Allergy & Immunology Authors: Barbara P. Yawn, Dennis Williams, Gregory Poland Tags: Editorial Source Type: research

Cutaneous reactions following COVID-19 vaccination assessed by dermatologists: a single-institutional study in Germany
CONCLUSIONS: It can be assumed that vaccination may trigger immune activation-related reactions especially in those patients predisposed to develop respective skin diseases.PMID:36892192 | DOI:10.1111/ddg.14987
Source: Herpes - March 9, 2023 Category: Infectious Diseases Authors: Rosi Wang Sonja Mathes Carla Claussen Tilo Biedermann Knut Brockow Source Type: research

Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA ® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
SPRING HOUSE, PENNSYLVANIA, May 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from the Phase 2 GALAXI 1 clinical trial of TREMFYA® (guselkumab) in adult patients with moderately to severely active Crohn’s disease (CD), and from three separate long-term pooled analyses of adult patients with ulcerative colitis (UC) and CD treated with STELARA® (ustekinumab).1,2,3,4 These data are being presented as oral and poster presentations and are among 29 Janssen abstracts presented during the Digestive Disease Week® (DDW) meeting taking place in person and virtually in San Di...
Source: Johnson and Johnson - May 24, 2022 Category: Pharmaceuticals Source Type: news

A Broad Safety Assessment of the Recombinant Herpes Zoster Vaccine
Am J Epidemiol. 2022 Feb 12:kwac030. doi: 10.1093/aje/kwac030. Online ahead of print.ABSTRACTThe recombinant herpes zoster vaccine (RZV), approved as a 2-dose series in the U.S. in October 2017, has proven highly effective and generally safe. However, a small risk of Guillain-Barré syndrome (GBS) after vaccination was identified post-approval, and questions remain about other possible adverse events. This data-mining study assessed RZV safety in the U.S. using the self-controlled tree-temporal scan statistic, scanning data on thousands of diagnoses recorded during follow-up to detect any statistically unusual temporal clu...
Source: Am J Epidemiol - February 13, 2022 Category: Epidemiology Authors: W Katherine Yih Martin Kulldorff Inna Dashevsky Judith C Maro Source Type: research

Janssen Reports Positive Topline Week 48 Phase 2 Results for TREMFYA ® (guselkumab) in Adults With Moderately to Severely Active Crohn's Disease
SPRING HOUSE, PENNSYLVANIA, November 17, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced topline results from the Phase 2 GALAXI 1 clinical trial which showed rates of clinical remission (Crohn’s Disease Activity Index [CDAI]<150) previously reported at week 12 increased at week 48 among adults with moderately to severely active Crohn’s disease (CD) treated with TREMFYA® (guselkumab).1 At week 48, 65 percent of patients receiving TREMFYA achieved clinical remission. TREMFYA is under investigation and not currently approved for the treatment of CD in the U.S.2Janssen previously...
Source: Johnson and Johnson - November 17, 2021 Category: Pharmaceuticals Source Type: news

From the Pages of Allergy Watch
For this month ’s issue of Annals, which focuses on vaccines, I’ve selected 3 article summaries from recent Allergy Watch that reviewed studies on various aspects of vaccines. The first reports data from the pivotal study showing the improved efficacy of the new recombinant subunit herpes zoster vaccine. The n ext review describes a report of a unique vaccine for cats that induces IgG blocking antibodies for Fel d 1. The last review shows discrepant results of pneumococcal titers from different labs.
Source: Annals of Allergy, Asthma and Immunology - April 23, 2020 Category: Allergy & Immunology Authors: David A. Khan, Gerald B. Lee, Stanley M. Fineman Tags: Special Series Source Type: research

From the pages of AllergyWatch
For this month's issue of Annals, which focuses on vaccines, there are 3 article summaries from recent AllergyWatch columns that reviewed studies on various aspects of vaccines. The first reports data from a pivotal study on the improved efficacy of the new recombinant subunit herpes zoster vaccine. The second review describes a report of a unique vaccine for cats that induces immunoglobulin G –blocking antibodies for Fel d 1. The third review reports discrepant results of pneumococcal titers from different laboratories.
Source: Annals of Allergy, Asthma and Immunology - April 23, 2020 Category: Allergy & Immunology Authors: David A. Khan, Gerald B. Lee, Stanley M. Fineman Tags: Special Series Source Type: research

Live Herpes Zoster Vaccine Fails to Provide Long-Term Protection in RA Patients on Tofacitinib Live Herpes Zoster Vaccine Fails to Provide Long-Term Protection in RA Patients on Tofacitinib
The live herpes zoster vaccine does not provide reliable long-term protection in rheumatoid arthritis (RA) patients taking tofacitinib, a recent study suggests.Reuters Health Information
Source: Medscape Allergy Headlines - April 20, 2020 Category: Allergy & Immunology Tags: Rheumatology News Source Type: news

P235 treatment patterns of influenza and zoster vaccinations in patients prescribed mepolizumab
This study examines the prevalence and patterns of influenza and herpes zoster vaccination among patients treated with mepolizumab in the real-world.
Source: Annals of Allergy, Asthma and Immunology - October 31, 2019 Category: Allergy & Immunology Authors: J. Llanos, J. Mao, M. Bogart, J. Silver, C. Blauer-Peterson, E. Hulbert, B. Hahn Source Type: research

Shingrix for Herpes Zoster: A Review Shingrix for Herpes Zoster: A Review
This brief primer reviews the pathophysiology of herpes zoster, and summarizes the results of the clinical trials of Shingrex, the newly approved recombinant vaccine for HZ prevention.Skin Therapy Letter
Source: Medscape Allergy Headlines - October 14, 2019 Category: Allergy & Immunology Tags: Dermatology Journal Article Source Type: news

Herpes Zoster after Recombinant Zoster Vaccine: A First Case Report
Publication date: Available online 2 August 2019Source: The Journal of Allergy and Clinical Immunology: In PracticeAuthor(s): Laurie A. Housel, Bruce M. McClenathan
Source: The Journal of Allergy and Clinical Immunology: In Practice - August 2, 2019 Category: Allergy & Immunology Source Type: research

Using the Self-Controlled Tree-Temporal Scan Statistic to Assess the Safety of Live Attenuated Herpes Zoster Vaccine.
Abstract The self-controlled tree-temporal scan statistic allows detection of potential vaccine- or drug-associated adverse events without pre-specifying the specific events or post-exposure risk intervals of concern. It thus opens a promising new avenue for safety studies. The method has been successfully used to evaluate the safety of two vaccines for adolescents and young adults, but its suitability to study vaccines for older adults had not been established. The current study applied the method to assess the safety of live attenuated herpes zoster vaccination during 2011-2017 in U.S. adults ≥ 60 years old, u...
Source: Am J Epidemiol - May 6, 2019 Category: Epidemiology Authors: Yih WK, Kulldorff M, Dashevsky I, Maro JC Tags: Am J Epidemiol Source Type: research

Investigational zoster vaccine effective, safe after age 70
The herpes zoster subunit vaccine was effective and safe for adults aged 70 and older in a phase III manufacturer-sponsored clinical trial, which was reported online in the New England Journal of Medicine. The ZOE-70 study (Zoster Efficacy Study in Adults 70 years of Age or Older) assessed an...
Source: Skin and Allergy News - September 14, 2016 Category: Dermatology Source Type: news

Pages: 1  2